A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months All seven patients treated still alive as of last follow-up at a median follow-up of 29.1 months NEW YORK, Jan. 17, 2023...
NEW YORK, Dec. 16, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company granted an equity award, previously approved by the Company's...
NEW YORK, Dec. 13, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement with certain...
NEW YORK, Dec. 8, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited...
Results show that percutaneous hepatic perfusion with CHEMOSAT® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in patients with inoperable, treatment-refractory liver metastases. NEW...
NEW YORK, Nov. 9, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to employment to two individuals. The employees received a total of...
NEW YORK, Nov. 8, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September...
NEW YORK, Oct. 24, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to...
NEW YORK, Sept. 1, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C. Wainwright 24th Annual Global Investor Conference. Delcath CEO,...
NEW YORK, Aug. 8, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30,...